DNA NANOBOTS, INC.
ProgrammableNon-Viral Gene Delivery
Reshaping Gene Therapy™
Structurally engineered DNA delivery, designed for payloads beyond the reach of viral vectors. All programs preclinical.
STAGE
Preclinical
ORIGIN
Spin-out from The Ohio State University
FOUNDATION
A decade of DNA-origami research
APPROACH
Non-viral, structurally engineered delivery
THE DELIVERY PROBLEM
Gene therapies are limited by the systems that deliver them.
Gene therapy has become approved medicine. The vehicles that carry genetic material into cells still set limits on which genes can be delivered intact, where a therapy is distributed, and whether a second dose is possible.
Payload constraints
Packaging capacity limits which genes can be carried intact. Full-length dystrophin, for example, exceeds the payload capacity of AAV.
Targeting and biodistribution
Reaching the intended tissue, and limiting exposure elsewhere. Distribution is largely determined by a vector’s inherent properties rather than by design.
Barriers to repeat administration
Immune responses can restrict who is eligible for a therapy and whether it can be given more than once.
STRUCTURAL RENDER · COMPANY-SUPPLIED
THE GENOBOT PLATFORM
Engineering the delivery structure itself.
Genobots are non-viral delivery systems built by folding a gene-bearing DNA scaffold into a defined nanoscale structure. Addressable positions on that structure are designed to hold the targeting and trafficking elements a program requires. The approach builds on more than a decade of foundational DNA-origami research at The Ohio State University.
DNA Nanobots is a platform technology company. The Genobot architecture is being evaluated across genetic diseases where these constraints bind, including Duchenne muscular dystrophy. No program has been designated a lead. All work is preclinical. DNA Nanobots has no approved products and is not currently conducting clinical trials.
COLLABORATION
Biopharma Partner Program
We work with biopharma companies, research institutions and rare-disease organizations where payload size, tissue targeting or repeat administration is the limiting factor. Collaborations range from early feasibility assessment through joint preclinical development.
DESIGN OBJECTIVES
What the architecture is being developed to do
Each objective below describes design intent under preclinical evaluation, not an established capability.
Large-payload architecture
Designed to accommodate genetic constructs beyond the practical capacity of common viral vectors.
Repeat-administration potential
A non-viral architecture being evaluated for tolerability and repeat administration.
Programmable targeting
Defined attachment sites are intended to support controlled placement of targeting and functional elements.
Let’s expand what gene therapy can reach.
For partnering, investment or scientific enquiries, get in touch.